Literature DB >> 35881224

Endotype of Chronic Rhinosinusitis with Nasal Polyps in Morocco.

Youssef Darouassi1, Mohamed Amine Azami2, Mohamed El-Akhiri3, Iliass Benchafai3, Mohamed Amine Hanine3, Mohamed Amine Haouane2, Youness Chebraoui3, Mossab Tayane3, Issam Rharrassi2, Mohamed Mliha Touati3, Abdelfettah Aljalil3, Haddou Ammar3.   

Abstract

BACKGROUND: With the advent of biotherapies, endotyping of chronic rhinosinusitis with nasal polyps (CRSwNP) is becoming more and more important to optimize therapeutic management. While the majority of CRSwNPs in the United States, Europe, and Japan exhibit type 2 eosinophil-dominant inflammation response, other parts of Asia display mixed patterns including neutrophil-dominant inflammation. Until now, no study has focused on the proportion of inflammation patterns in Morocco or anywhere on the African continent. We aim to fill this gap by studying tissue inflammatory response in our operated patients.
MATERIAL AND METHODS: After searching the database of the pathology department, we retrieved from the archives the stained pathology slides of all our patients who underwent surgery for CRSwNP over 5 years from 2017 to 2021. We counted then the number of eosinophils in the lamina propria at high-power magnification to determine the predominant inflammatory pattern.
RESULTS: A total of 35 reports were collected. We found that eosinophilic inflammation was predominant, accounting for 97% of the cases.
CONCLUSIONS: The CRSwNP endotype in our region would mainly be type 2. However, our results must be confirmed by multicenter studies involving a large number of patients.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Biologics; Chronic rhinosinusitis; nasal polyps; Endotypes; Pharmacotherapy; Surgery; Type 2 inflammation

Year:  2022        PMID: 35881224     DOI: 10.1007/s12105-022-01477-y

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  1 in total

Review 1.  State-of-the-art overview on biological treatment for CRSwNP.

Authors:  P W Hellings; E Verhoeven; W J Fokkens
Journal:  Rhinology       Date:  2021-04-01       Impact factor: 3.681

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.